GSK joins Boehringer and AstraZeneca in capping out-of-pocket costs for inhalers

GSK will cap out-of-pocket costs for its inhalers at $35, making it the third major drugmaker to agree to limit patients’ spending amid significant US political pressure over the price of commonly used medications.

In total, nine GSK products will have their out-of-pocket costs capped, according to the UK company. In addition, the wholesale acquisition cost for Advair Diskus has been reduced by an average of 50% and Advair HFA by an average of 20%.

GSK said it would share more details closer to the start of the program, which will begin no later than Jan. 1, 2025.

“This new commitment, combined with our existing offerings, will help even more patients living with asthma or COPD,” Maya Martinez-Davis, president of GSK’s US commercial operations, said in a statement.

Both Boehringer and AstraZeneca already capped their inhaler costs earlier this month, and also reduced the…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks